<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"><channel><title><![CDATA[Timothy Ives]]></title><description><![CDATA[Researcher, educator and clinician exploring how evidence moves through health systems—and what happens to it along the way.]]></description><link>https://www.evidenceintransit.com</link><image><url>https://substackcdn.com/image/fetch/$s_!Makq!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbf37a8ea-fbe1-49b6-a851-77eef2bae6ee_726x726.png</url><title>Timothy Ives</title><link>https://www.evidenceintransit.com</link></image><generator>Substack</generator><lastBuildDate>Sun, 22 Nov 2026 01:31:41 GMT</lastBuildDate><atom:link href="https://www.evidenceintransit.com/feed" rel="self" type="application/rss+xml"/><copyright><![CDATA[Timothy Ives]]></copyright><language><![CDATA[en]]></language><webMaster><![CDATA[timothyives@substack.com]]></webMaster><itunes:owner><itunes:email><![CDATA[timothyives@substack.com]]></itunes:email><itunes:name><![CDATA[Timothy Ives]]></itunes:name></itunes:owner><itunes:author><![CDATA[Timothy Ives]]></itunes:author><googleplay:owner><![CDATA[timothyives@substack.com]]></googleplay:owner><googleplay:email><![CDATA[timothyives@substack.com]]></googleplay:email><googleplay:author><![CDATA[Timothy Ives]]></googleplay:author><itunes:block><![CDATA[Yes]]></itunes:block><item><title><![CDATA[What Exactly Does a Company Have to Prove]]></title><description><![CDATA[Evidence in Transit &#8212; Part 2 When does a scientific observation become a claim?]]></description><link>https://www.evidenceintransit.com/p/what-exactly-does-a-company-have</link><guid isPermaLink="false">https://www.evidenceintransit.com/p/what-exactly-does-a-company-have</guid><dc:creator><![CDATA[Timothy Ives]]></dc:creator><pubDate>Tue, 10 Nov 2026 13:01:17 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!67wL!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!67wL!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!67wL!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 424w, https://substackcdn.com/image/fetch/$s_!67wL!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 848w, https://substackcdn.com/image/fetch/$s_!67wL!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!67wL!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!67wL!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg" width="1456" height="636" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/eb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:636,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:8955813,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.evidenceintransit.com/i/224299492?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!67wL!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 424w, https://substackcdn.com/image/fetch/$s_!67wL!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 848w, https://substackcdn.com/image/fetch/$s_!67wL!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!67wL!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feb2bbab5-7d0e-449a-a2fe-28bb5acbfc16_6592x2880.jpeg 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>In Part 1, I admitted that I didn&#8217;t understand the regulatory difficulties facing Xlear nearly as well as I thought I did.</p><p>That wasn&#8217;t the first time I&#8217;d discovered a gap in my understanding.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.evidenceintransit.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>A few years earlier, I had walked into a room full of specialist rhinologist surgeons and nurses, reasonably confident that I knew something they didn&#8217;t.</p><p>As it turned out, I was wrong.</p><p>The room was at the ENT department at Charing Cross Hospital in London, part of Imperial College Healthcare.</p><p>Xlear had invited me to speak to the team about xylitol nasal sprays. I managed to secure an hour of their time.</p><p>The promise of lunch may have helped.</p><p>What I hadn&#8217;t realised was that they were already using xylitol in their clinical practice.</p><p><strong>An unexpected discovery</strong></p><p>The surgical team explained that they were using Xlear&#8217;s xylitol-containing nasal irrigation sachets, prepared with sterile water, during surgery. They also provided patients with the preparation for use during the first week afterwards.</p><p>The lead surgeon was particularly knowledgeable about xylitol and its potential effects on biofilms.</p><p>I had expected to spend much of my hour introducing the science.</p><p>Instead, I found myself discussing it with people who had already incorporated a related product into their clinical routines.</p><p>They were also interested in the nasal sprays. The samples were enthusiastically received, and I understood that the team intended to recommend them to patients.</p><p>I left feeling that the meeting had gone rather well.</p><p>But looking back, I realise there were questions I never asked.</p><p>Why had they started using xylitol irrigation in the first place? Had they been influenced by published research, by another surgeon, or by their own clinical observations? Was this a formal departmental protocol or a practice developed within the team?</p><p>I still don&#8217;t know.</p><p>And perhaps more importantly, what did their use of the preparation actually tell me about its effectiveness?</p><p>At the time, I was interested in introducing a product to clinicians.</p><p>Today, I&#8217;m interested in understanding how knowledge reached those clinicians before I did.</p><p>I suspect there&#8217;s another story waiting to be uncovered there.</p><p><strong>When experience becomes evidence</strong></p><p>The Charing Cross encounter presents a problem that I suspect many clinicians will recognise.</p><p>We observe things happening in practice. We notice patterns. We hear patients describe improvements. Sometimes we change what we do.</p><p>But what exactly have we learned?</p><p>The surgeons&#8217; use of xylitol told me that a specialist team considered it worth incorporating into its practice. Their knowledge of the biofilm literature suggested a scientific rationale behind their interest.</p><p>Yet neither observation demonstrated that xylitol irrigation improved postoperative outcomes compared with saline alone.</p><p>Nor could experience with irrigation sachets automatically establish the effectiveness of a nasal spray.</p><p>A laboratory study might demonstrate that xylitol affects bacterial behaviour or biofilm formation under particular experimental conditions. That could provide a reason to investigate its clinical potential.</p><p>But the human nose is not a laboratory dish.</p><p>And the presence of a plausible mechanism doesn&#8217;t establish that a finished product prevents infection or improves recovery.</p><p>I have encountered this distinction repeatedly during my years working with xylitol in dentistry.</p><p>Evidence relating to an ingredient is not necessarily evidence relating to every product containing that ingredient.</p><p>Equally, evidence of an effect in one clinical context cannot simply be transferred to another.</p><p>This is where my two perspectives begin to pull in slightly different directions.</p><p>The clinician in me is interested in what practitioners observe and whether their experience might point towards something useful.</p><p>The investigator wants to know what else could explain those observations.</p><p>Neither perspective is necessarily wrong.</p><p>But they are asking different questions.</p><p><strong>One bottle, several possible claims</strong></p><p>Returning to Nathan Jones&#8217;s concerns from Part 1, I began wondering what a regulator would actually be asked to assess.</p><p>Consider a nasal spray containing xylitol.</p><p>Suppose its manufacturer wants to describe it as helping to moisturise the nasal passages.</p><p>Now suppose the manufacturer wants to claim that it relieves particular nasal symptoms.</p><p>Or that it prevents a respiratory infection.</p><p>These are illustrative claims, not a verified list of Xlear&#8217;s current UK or European claims.</p><p>The bottle might be identical in each example. Its ingredients might be unchanged.</p><p>But what the manufacturer is asking the public to believe is different.</p><p>And that difference matters.</p><p><strong>Then came COVID-19</strong></p><p>During the pandemic, researchers in Utah and Geneva investigated whether Xlear&#8217;s nasal spray formulation could affect SARS-CoV-2 under laboratory conditions.</p><p>The findings appeared encouraging. Experiments reported reductions in viral infectivity when the formulation was tested against the virus.</p><p>But what had actually been demonstrated?</p><p>The experiments were conducted outside the human body.</p><p>They raised the possibility of a useful effect, but they did not establish that using the nasal spray would prevent COVID-19 or improve outcomes in infected patients.</p><p>And that distinction was about to become more than an academic question.</p><p>Xlear&#8217;s COVID-19 advertising claims subsequently attracted the attention of the US Federal Trade Commission.</p><p>The FTC challenged whether the evidence adequately substantiated the claims being made. Xlear disputed the allegations, and the legal proceedings were eventually dismissed in 2025 without a judicial determination of the spray&#8217;s clinical effectiveness.</p><p>Small clinical investigations also followed the laboratory work, adding further observations and questions to the developing evidence.</p><p>Suddenly, the relationship between an experimental observation and a public claim had become the subject of a real regulatory dispute.</p><p>How far could a manufacturer legitimately travel from <em>this formulation affected a virus under laboratory conditions</em> to <em>this product protects people against infection</em>?</p><p>The distinction might seem straightforward when written down.</p><p>But the journey between those statements is anything but simple.</p><p><strong>Does the existing evidence count?</strong></p><p>This brings us to something that initially troubled me.</p><p>If research has already been published on xylitol, why might a manufacturer need to undertake further studies?</p><p>Surely existing evidence should count for something?</p><p>The answer appears to be yes.</p><p>But precisely what it counts towards depends on the claim being made.</p><p>In Great Britain, the regulatory requirements for a nasal product depend on factors including its intended purpose and how its principal action is achieved. A product may fall within medical-device or medicines legislation, with different requirements applying.</p><p>The European Union has related but distinct frameworks.</p><p>Under the EU medical-device framework, for example, clinical evaluation can draw upon existing scientific literature and, where relevant requirements are met, evidence from equivalent devices. It does not automatically follow that every product requires an entirely new clinical trial.</p><p>But the evidence still needs to support the particular product and its intended purpose.</p><p>A laboratory study demonstrating an effect on a virus might support a proposed mechanism.</p><p>A clinical study examining nasal symptoms might investigate whether patients experience a benefit.</p><p>A controlled trial demonstrating that a particular spray reduces the risk of infection would address another question.</p><p>Those studies are not interchangeable.</p><p>This doesn&#8217;t mean the earlier research has no value.</p><p>It means we need to be careful about what we ask it to establish.</p><p><strong>What about the people using it?</strong></p><p>There is another part of the story I don&#8217;t want to lose.</p><p>People have been purchasing and using xylitol nasal products for years.</p><p>What should we make of that experience?</p><p>Sales figures might tell us that a product attracts customers. Repeat purchases might suggest that people find it useful or worthwhile. Reports of benefit might point towards effects that deserve investigation.</p><p>But none of those observations, by themselves, establishes that the product prevents a viral infection or produces a particular clinical outcome.</p><p>Equally, dismissing people&#8217;s experiences simply because they are not controlled clinical trials would seem unsatisfactory.</p><p>Those experiences may help us formulate questions, identify outcomes worth measuring and understand how products are used outside research settings.</p><p>Perhaps the question is not whether experience counts as evidence.</p><p>Perhaps it is <strong>what kind of evidence experience provides, and what further questions it allows us to ask.</strong></p><p><strong>Two sides of the Atlantic</strong></p><p>Nathan&#8217;s original frustration concerned the different regulatory environments in which Xlear operates.</p><p>That makes the comparison between the United States and Europe unavoidable.</p><p>But I am becoming wary of reducing the disagreement to a simple story in which one regulator welcomes innovation while another obstructs it.</p><p>Both systems distinguish between products and the claims made about them. Both have processes for evaluating safety and effectiveness. Both can require manufacturers to substantiate what they say.</p><p>The differences lie in the details: classification, applicable legislation, permitted claims, evidence requirements and routes to market.</p><p>Before concluding that one system is unnecessarily restrictive, I would want to know exactly which claim Xlear wishes to make, how the product is classified in each market, what evidence has been submitted and what the relevant authorities have actually required.</p><p>I don&#8217;t yet have those answers.</p><p>Nor have I established the full regulatory history of Xlear&#8217;s nasal spray in the UK or EU, or the costs associated with any particular proposed claim.</p><p>Those gaps are important.</p><p>I began this investigation because Nathan&#8217;s account suggested a regulatory difficulty worth understanding.</p><p>It would be a mistake to turn his account into my conclusion before investigating it.</p><p><strong>Back to Charing Cross</strong></p><p>I keep returning to that meeting.</p><p>The surgeons were interested in xylitol&#8217;s potential benefits. They had incorporated a related irrigation preparation into their practice. They received the nasal sprays positively.</p><p>I had interpreted the meeting as a successful educational visit.</p><p>And perhaps it was.</p><p>But I now see something else.</p><p>The same encounter could be viewed in several ways.</p><p>To a clinician, it might be an example of professional judgement informed by scientific knowledge and experience.</p><p>To a researcher, it might be the beginning of a question about comparative effectiveness.</p><p>To a manufacturer, it might suggest an opportunity for further product development.</p><p>To a regulator, it would raise questions about the intended use and the evidence supporting any claims.</p><p>The encounter hasn&#8217;t changed.</p><p>What has changed is the boundary around which I am examining it.</p><p>I went to Charing Cross thinking I had something to teach.</p><p>I left having learned something unexpected.</p><p>Years later, I am discovering that I still have questions about what happened in that room.</p><p>And that brings me back to Xlear.</p><p><strong>The question is no longer simply whether evidence exists. It is whether the evidence available can support the particular claim being made about the particular product.</strong></p><p>That is a more demanding question.</p><p>It is also a more useful one.</p><p>But where did this particular journey begin?</p><p>The answer takes us back to a family physician, a young granddaughter suffering recurrent ear infections, and research into xylitol that had originally been conducted for quite different reasons.</p><p>I know something of that history.</p><p>What I don&#8217;t yet know is how the physician himself remembers it.</p><p>And that seems a good place for the next part of this investigation to begin.</p><p><strong>Next in Evidence in Transit: From a Granddaughter to a Nasal Spray &#8212; How an Idea Begins to Travel</strong></p><p><strong>Disclosure:</strong> I have worked with Xlear in an educational capacity for many years and continue to receive payment from the company for educational work. Xlear has no editorial control over <em>Evidence in Transit</em>. The views, questions and interpretations expressed here are my own.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.evidenceintransit.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[The Same Evidence, a Different Claim]]></title><description><![CDATA[What happens when evidence crosses a regulatory boundary?]]></description><link>https://www.evidenceintransit.com/p/the-same-evidence-a-different-claim</link><guid isPermaLink="false">https://www.evidenceintransit.com/p/the-same-evidence-a-different-claim</guid><dc:creator><![CDATA[Timothy Ives]]></dc:creator><pubDate>Tue, 29 Sep 2026 16:31:09 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!ztAy!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg" length="0" type="image/jpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!ztAy!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!ztAy!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ztAy!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ztAy!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ztAy!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!ztAy!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg" width="1456" height="636" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:636,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:8955813,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://timothyives.substack.com/i/218033812?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!ztAy!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 424w, https://substackcdn.com/image/fetch/$s_!ztAy!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 848w, https://substackcdn.com/image/fetch/$s_!ztAy!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!ztAy!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F656a108a-ce7b-4d9b-8dd2-3648781f2352_6592x2880.jpeg 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Yesterday, an email landed in my inbox from someone I have known for many years.</p><p>Nathan Jones is one of the owners of Xlear, an American company probably best known for making a rather simple nasal spray. Its <a href="https://xlear.com/products/xlear-nasal-spray-with-xylitol">original formulation </a>contains just four ingredients: purified water, xylitol, sodium chloride and grapefruit seed extract.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.evidenceintransit.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p>My relationship with Xlear goes back a long way.</p><p>For more than two decades, xylitol has wandered in and out of my professional life. I first became interested in it through dentistry, subsequently used it in clinical practice, wrote and lectured about it, and eventually found myself working educationally with Xlear. Over the years they have supported some of my professional activities, and I have come to know several of the people behind the company.</p><p>That relationship is worth declaring at the beginning, because this is not going to be an advertisement for Xlear.</p><p>Nor, I suspect, is it really going to be a story about xylitol.</p><p>Nathan&#8217;s email concerned something quite different.</p><p>He was frustrated by regulation.</p><p>His argument was that changes in European regulation had made it increasingly difficult for products such as theirs to be sold while making meaningful claims about what they might do. He believed the evidential and financial hurdles involved increasingly favoured large pharmaceutical companies over smaller businesses.</p><p>I have heard versions of that argument before.</p><p>This time, though, I found myself wondering whether I actually understood it.</p><p>I didn&#8217;t.</p><p>And that seemed a much more interesting place to begin.</p><h3>Evidence is not one thing</h3><p>Perhaps I stopped because xylitol is not new to me.</p><p>I first encountered it seriously more than twenty years ago, at a dental meeting in New York. What began as an interest in dental caries gradually took me much further: into saliva, bacterial behaviour, diet, otitis media, nasal health and, eventually, some rather unexpected conversations about respiratory infection.</p><p>Along the way I read the research, incorporated xylitol into clinical protocols, watched patients use it, spoke about it internationally and met some of the researchers and companies involved.</p><p>So when Nathan wrote about the difficulties Xlear had encountered in Europe, I already knew there was a body of evidence sitting behind the conversation.</p><p>But evidence is not one thing.</p><p>A laboratory experiment demonstrating an effect is not the same as a clinical trial. Evidence concerning an ingredient is not necessarily evidence concerning a finished product. A plausible biological mechanism does not establish that something will improve a meaningful outcome in a patient.</p><p>Those distinctions matter.</p><p>They should matter.</p><p>If a company tells us that a product can prevent or treat disease, we should expect evidence appropriate to that claim. Regulation exists, at least in part, to protect us from products whose promises run ahead of their evidence.</p><p>And yet Nathan&#8217;s email raised a different question.</p><p>What happens when evidence does exist, but the system through which it must travel determines what can be said about it?</p><h3>Crossing the border</h3><p>The original Xlear nasal spray is remarkably simple.</p><p>Purified water. Xylitol. Sodium chloride. Grapefruit seed extract.</p><p>Put the bottle on a table in Utah and then put the same bottle on a table in London. Nothing inside it has changed.</p><p>The formulation is the same.</p><p>The published research has not suddenly become different because the bottle crossed the Atlantic.</p><p>And yet something has changed.</p><p>For the person using it, that change may be much less abstract.</p><p>Imagine someone who has routinely bought the spray in the United States moving to the UK. The product they used yesterday has not changed. Their reasons for using it have not changed. But their ability to find it, buy it, or understand what it is supposed to do may now be different.</p><p>From inside a regulatory system, that difference may represent protection. From inside the life of the person using the product, it may simply feel like a barrier.</p><p>I became interested in that distance too.</p><p>What the company can say about that bottle, how the product is classified, what evidence may be required to support particular claims, and ultimately how it can be presented to clinicians and the public are determined by the <a href="https://www.gov.uk/government/publications/category-lists-following-implementation-of-the-windsor-framework/category-lists-of-products">regulatory system</a> in which it now sits.</p><p>At first glance, that seems entirely reasonable.</p><p>Different countries have different rules. Health claims require scrutiny. Consumers need protection. A manufacturer should not be able to turn an interesting laboratory finding into a promise of clinical benefit simply by changing the wording on a label.</p><p>But the simplicity of the bottle began to expose the complexity surrounding it.</p><p>Imagine that one of its ingredients has been shown to do something interesting in a laboratory.</p><p>What can the researcher who conducted the experiment say?</p><p>What can I, as a clinician or educator, say when discussing that research?</p><p>What can a journalist say about it?</p><p>And what can the company selling the product say?</p><p>Those questions sound similar.</p><p>Legally and scientifically, they may be very different.</p><p>Somewhere between an observation in a laboratory and a sentence printed on a bottle, evidence crosses a boundary.</p><p>I began to wonder what happens to it there.</p><h3>A claim worth testing</h3><p>Nathan has an explanation.</p><p>He believes the regulatory environment in Europe has become increasingly difficult for companies such as Xlear to navigate. More importantly, he argues that demonstrating what they would need to demonstrate to make certain health claims could require considerable investment in both time and money.</p><p>That is quite a claim.</p><p>It would be easy to repeat it.</p><p>It would also be easy to dismiss it as the frustration of a business owner encountering a regulatory system designed to protect the public.</p><p>Neither seemed particularly satisfactory.</p><p>What I wanted to know was whether it was true.</p><p>What would Xlear actually have to demonstrate to make a particular health claim in Britain?</p><p>Could existing research be used?</p><p>Would evidence concerning xylitol itself count, or would the finished nasal spray need to be investigated separately?</p><p>Would laboratory evidence contribute anything?</p><p>Would clinical trials be required?</p><p>And, eventually, the wonderfully simple question:</p><p><strong>How much would it cost?</strong></p><p>I realised that I didn&#8217;t know the answers to these questions.</p><p>So rather than arguing about the system, I decided to follow the evidence through it.</p><h3>Evidence in Transit</h3><p>That is where this investigation begins.</p><p>I am not starting from the assumption that Nathan is right. Nor am I starting from the assumption that the regulatory system is wrong.</p><p>I want to understand what happens in between.</p><p>Over the coming investigations, I will follow the published research and regulatory documents and, where possible, speak with people who understand different parts of the journey.</p><p>Xlear provides the first case, but I suspect the questions it raises extend well beyond one company, one product or even xylitol. Ultimately, regulatory decisions are not experienced only by companies. They shape what clinicians can recommend, what patients can access and what the public is told.</p><p>Because somewhere underneath this rather ordinary bottle of nasal spray sits a much larger question:</p><p><strong>What happens to evidence as it travels through systems?</strong></p><p>That is what <em>Evidence in Transit</em> will try to find out.</p><h3>Next: What exactly would Xlear have to prove?</h3><p>Before asking whether the regulatory burden is reasonable, we first need to establish what that burden actually is.</p><p>What evidence would be required for Xlear to make specific health claims about its nasal spray in the UK and the EU, and how much of the evidence that already exists would count?</p><p><em><strong>Disclosure:</strong> I have worked with Xlear in an educational capacity over many years, and the company has supported some of my professional activities. Xlear has no editorial control over Evidence in Transit. Relevant relationships will be declared throughout this investigation.</em></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.evidenceintransit.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item></channel></rss>